Shawver Laura 4

What Happened
Laura Shawver, a director of ARS Pharmaceuticals (SPRY), was granted a derivative award of 30,000 shares on June 24, 2026. The award shows an acquisition price of $0.00 (no cash paid at grant). The filing classifies this as a grant/award (derivative instrument) rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-24; filing date: 2026-06-26 (filed within the two-business-day Form 4 window).
• Instrument: Derivative award of 30,000 shares; reported acquisition price $0.00.
• Shares owned after transaction: Not specified in the filing.
• Footnote: The shares subject to the award/option vest in full on the earlier of June 24, 2027 or the date of the issuer’s 2027 annual meeting of stockholders.
• No indication of a Section 16(c) sale, 10b5-1 plan, or tax-withholding sale in this filing.

Context
This is an equity-compensation grant to a director, not an open-market purchase or sale. Such awards are common for executive/director compensation and do not necessarily signal immediate bullish or bearish trading intent since the shares are subject to future vesting. The award does not involve an immediate exercise-and-sell (cashless) event; value will depend on future vesting and the company’s stock price at that time.